|
DE60310944T3
(de)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Weitere neue formen von interferierende rns moleküle
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
EP1633890B2
(en)
*
|
2003-06-02 |
2020-11-18 |
University of Massachusetts |
METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
|
|
PT1633767T
(pt)
*
|
2003-06-02 |
2019-02-27 |
Univ Massachusetts |
Métodos e composições para controlar a eficácia do silenciamento de arn
|
|
US7750144B2
(en)
*
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
DK2821085T3
(da)
*
|
2003-09-12 |
2020-08-03 |
Univ Massachusetts |
Rna-interferens til behandling af "gain-of-function"-forstyrrelser
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
CA2559955C
(en)
*
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
EP1937066A4
(en)
|
2005-08-18 |
2008-12-24 |
Alnylam Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
|
|
ES2911034T3
(es)
|
2006-08-08 |
2022-05-17 |
Univ Bonn Rheinische Friedrich Wilhelms |
Estructura y uso de oligonucleótidos 5' fosfato
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
WO2009141146A1
(en)
|
2008-05-21 |
2009-11-26 |
Gunther Hartmann |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
WO2010021720A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
KR101728655B1
(ko)
*
|
2008-12-18 |
2017-04-19 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US11414664B2
(en)
|
2008-12-18 |
2022-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010111471A2
(en)
*
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2756845B1
(en)
*
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
CN103555722B
(zh)
|
2009-04-03 |
2016-08-31 |
戴瑟纳制药公司 |
利用不对称双链rna特异性抑制kras的方法和组合物
|
|
WO2011005363A2
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
EP2440666B1
(en)
|
2009-06-10 |
2017-03-01 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011072082A2
(en)
*
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
AU2011276365B2
(en)
|
2010-07-06 |
2017-05-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
|
|
AU2011276363A1
(en)
|
2010-07-06 |
2013-01-10 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2625189B1
(en)
*
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
EP2681314B1
(en)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
DK2718442T3
(en)
|
2011-06-10 |
2017-08-14 |
Temasek Life Sciences Laboratory Ltd |
GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR SUBPHYLA OF PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
CN107266391B
(zh)
|
2011-10-18 |
2020-04-17 |
迪克纳制药公司 |
胺阳离子脂质及其用途
|
|
SI3366775T2
(sl)
|
2011-11-18 |
2025-12-31 |
Alnylam Pharmaceuticals, Inc. |
Modificirana sredstva RNAI
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
EP2817287B1
(en)
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2839007B1
(en)
|
2012-04-19 |
2017-12-27 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
CA2893824A1
(en)
*
|
2012-12-14 |
2014-06-19 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
|
|
CN105142614A
(zh)
|
2013-03-14 |
2015-12-09 |
迪克纳制药公司 |
用于配制阴离子试剂的方法
|
|
BR112015022855A2
(pt)
|
2013-03-14 |
2017-11-07 |
Shire Human Genetic Therapies |
composições e método para produção de um anticorpo in vitro
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US9458457B2
(en)
|
2013-07-03 |
2016-10-04 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
US10150965B2
(en)
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
EP3581654B1
(en)
|
2013-12-27 |
2021-03-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
|
|
AU2015330670B2
(en)
|
2014-10-10 |
2022-01-06 |
Novo Nordisk Health Care Ag |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
DK3569711T3
(da)
|
2014-12-15 |
2021-02-22 |
Dicerna Pharmaceuticals Inc |
Ligandmodificerede dobbeltstrengede nukleinsyrer
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
US10689647B2
(en)
|
2015-05-08 |
2020-06-23 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
|
|
US10758624B2
(en)
*
|
2015-07-02 |
2020-09-01 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
HUE059718T2
(hu)
|
2016-09-02 |
2022-12-28 |
Dicerna Pharmaceuticals Inc |
4'-foszfát analógok és azokat tartalmazó oligonukleotidok
|
|
US11298371B2
(en)
*
|
2017-10-11 |
2022-04-12 |
Nitto Denko Corporation |
Regulation of nucleic acid molecule expression
|
|
WO2019075419A1
(en)
|
2017-10-13 |
2019-04-18 |
Dicerna Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
|
|
UA128786C2
(uk)
|
2017-10-20 |
2024-10-23 |
Дайсерна Фармасьютикалз, Інк |
Олігонуклеотид для лікування інфекції гепатиту в
|
|
US11813280B2
(en)
|
2018-01-05 |
2023-11-14 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
KR20200109311A
(ko)
|
2018-01-16 |
2020-09-22 |
다이서나 파마수이티컬, 인크. |
Aldh2 발현을 억제하기 위한 조성물 및 방법
|
|
CN112534055A
(zh)
|
2018-07-13 |
2021-03-19 |
豪夫迈·罗氏有限公司 |
用于调节rtel1表达的寡核苷酸
|
|
WO2020051231A1
(en)
|
2018-09-04 |
2020-03-12 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
|
US11452738B2
(en)
|
2019-01-04 |
2022-09-27 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
|
|
EP3908661A1
(en)
|
2019-02-12 |
2021-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of cyp27a1
|
|
BR112021018739A2
(pt)
|
2019-03-29 |
2022-05-03 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
|
|
BR112021019793A2
(pt)
|
2019-04-04 |
2021-12-07 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para inibir expressão de gene no sistema nervoso central
|
|
AU2020268798A1
(en)
|
2019-05-03 |
2021-11-04 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
BR112022003861A2
(pt)
|
2019-08-30 |
2022-05-24 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos ligando-2'-modificados, síntese dos mesmos, e intermediários para os mesmos
|
|
AU2020358016A1
(en)
|
2019-10-02 |
2022-04-21 |
Dicerna Pharmaceuticals, Inc. |
Chemical modifications of small interfering RNA with minimal fluorine content
|
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
US20230287425A1
(en)
|
2020-03-18 |
2023-09-14 |
Dicerna Pharmacuticals Inc. |
Compositions and methods for inhibiting angptl3 expression
|
|
KR20230061389A
(ko)
|
2020-08-04 |
2023-05-08 |
다이서나 파마수이티컬, 인크. |
올리고뉴클레오티드의 전신 전달
|
|
CA3190481A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting plp1 expression
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
US12435336B2
(en)
|
2020-08-05 |
2025-10-07 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting LPA expression
|
|
TW202221122A
(zh)
|
2020-08-05 |
2022-06-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｂ型肝炎患者之寡核苷酸治療
|
|
PE20250400A1
(es)
|
2021-04-12 |
2025-02-11 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para inhibir cetohexoquinasa
|
|
CA3209418A1
(en)
|
2021-04-14 |
2022-10-20 |
Utsav SAXENA |
Compositions and methods for modulating pnpla3 expression
|
|
WO2022223515A2
(en)
|
2021-04-19 |
2022-10-27 |
Novo Nordisk A/S |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
|
EP4347820A1
(en)
|
2021-05-28 |
2024-04-10 |
Novo Nordisk A/S |
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression
|
|
EP4392556A1
(en)
|
2021-08-25 |
2024-07-03 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting ?lpha-1 antitrypsin expression
|
|
KR20240101580A9
(ko)
|
2021-11-11 |
2025-12-10 |
에프. 호프만-라 로슈 아게 |
Hbv 치료를 위한 약학 조합물
|
|
JP2024543195A
(ja)
|
2021-12-01 |
2024-11-19 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ａｐｏｃ３発現を調節するための組成物及び方法
|
|
US20230374522A1
(en)
|
2022-04-15 |
2023-11-23 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating scap activity
|
|
CN119173631A
(zh)
|
2022-05-12 |
2024-12-20 |
迪克纳制药公司 |
用于抑制mapt表达的组合物和方法
|
|
IL316843A
(en)
|
2022-05-13 |
2025-01-01 |
Dicerna Pharmaceuticals Inc |
Compounds and methods for inhibiting SNCA deactivation
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
IL326017A
(en)
|
2023-07-28 |
2026-03-01 |
Novo Nordisk As |
Compositions and methods for expressing programmed death ligand receptor (PD-L1)
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
US20260055414A1
(en)
|
2024-08-21 |
2026-02-26 |
Novo Nordisk A/S |
Compositions and methods for inhibiting xdh expression
|
|
WO2026083241A1
(en)
|
2024-10-15 |
2026-04-23 |
Genevant Sciences Gmbh |
Ionizable lipids comprising n,n-substituted hydroxylamine esters
|